

New Journal of Chemistry - RSC

Supporting information

Palladium supported on magnesium hydroxyl fluoride: an effective acid catalyst for the hydrogenation of imines and N-heterocycles

Reshma Kokane,^{a,b} Yann Corre,^{c,d} Erhard Kemnitz,^e Mohan K. Dongare,^f Francine Agbossou-Niedercorn,^c Christophe Michon,^{*c,d,g} Shubhangi Umbarkar^{*a,b}

^a *Catalysis Division, CSIR-National Chemical Laboratory, Dr. Homi Bhabha Road,
Pune—41108 (India)*

^b *Academy of Scientific and Innovative Research, CSIR, New Delhi-110 001, India.*

^c *Univ. Lille, CNRS, Centrale Lille, ENSCL, Univ. Artois, UMR 8181 - UCCS –
Unité de Catalyse et Chimie du Solide, F-59000 Lille, France.*

^d *Centrale Lille, Bat C7, Cité Scientifique, CS20048, 59651 Villeneuve d'Ascq Cedex, France*

^e *Institute of Chemistry, Humboldt University, Brook-Taylor-Straße 2,
12489 Berlin (Germany)*

^f *Malati Fine Chemicals Pvt. Ltd., Panchawati, Pune—411008 (India)*

^g *Université de Strasbourg, Université de Haute-Alsace, Ecole Européenne de Chimie,
Polymères et Matériaux, CNRS, LIMA, UMR 7042, 25 rue Becquerel, 67087 Strasbourg,
France.*

cmichon@unistra.fr, *Tel.:* +33(0)3 68 85 27 97

sb.umbarkar@ncl.res.in, *Fax:* +91 20 25902633, *Tel.:* +91 20 25902044

I) General remarks.	2
II) General procedures.	2
III) Characterization of compounds.	6
IV) References.	13
V) ¹ H, ¹³ C NMR spectra of isolated compounds.	14

I) General Remarks.

All solvents were dried using standard methods and stored over molecular sieves (4 Å). All reactions were carried out under a dry nitrogen atmosphere and were repeated at least twice. Analytical thin layer chromatography (TLC) was performed on Merck pre-coated 0.20 mm silica gel Alugram Sil 60 G/UV₂₅₄ plates. Flash chromatography was carried out with Macherey silica gel (Kieselgel 60). ¹H (300 MHz), ¹³C (75 MHz), ¹⁹F (282 MHz) NMR spectra were acquired on Bruker Avance I and II spectrometers. Coupling constants are expressed in Hz. ¹H NMR shifts are given relative to the residual solvent resonances at 7.26 ppm, and ¹³C NMR shifts are given relative to the residual solvent peak of CDCl₃ (77.16 ppm). 1,3,5-trimethoxybenzene and 1,2,4,5-tetrachlorobenzene were used as internal standards when needed Gas chromatography analyses were done on GC Shimadzu 2010+ with FID detectors using Supelco SPB-5 column (30 m, 0.25 mm, 0.25 μm) and with nitrogen as gas carrier. GC-MS analyses were performed on a Shimadzu QP2010+ (EI mode) using Supelco column SLBTM-5ms (30m, 0.25mm, 0.25μm). All commercial reagents and solvents were used as received unless otherwise stated. Imine reagents **1a**,^{S1} **1b**,^{S2} **1c**,^{S3} **1d**,^{S4} **1e**,^{S3} **1f**,^{S4} **1g**,^{S3} **3a**,^{S1} **3b**,^{S5} **3c**,^{S6} **3d**,^{S1} **3e**,^{S1} **3f**,^{S1} **3g**,^{S1} **3h**^{S7} were prepared as reported.

II) General Procedure for catalysts synthesis, characterizations and the catalyzed hydrogenation reactions.

Catalysts synthesis

CAUTION: HF is a highly toxic acid which causes severe burns when in contact with skin!

Synthesis of catalyst (1PMF-ppt) by coprecipitation method^{S8}

Under a well ventilated fume hood, a slurry of magnesium oxide (3.193 g) in 50 mL methanol and 10 mL distilled water was prepared in a 250 mL polypropylene beaker. Under stirring, a sub-stoichiometric amount of hydrofluoric acid (1.2 equivalents, 7 mL 40% aq.) was added dropwise. After dissolution of MgO in aqueous HF, palladium acetate (1 wt %) dissolved in methanol (10 mL) was then added under stirring over a period of 45 min. The reaction mixture was subsequently stirred for an additional 3 h and further heated in a water bath at 80 °C until complete evaporation of solvent and formation of a powder. Finally, the prepared catalyst (1PMF-ppt) was heated at 250 °C in air for 5 h.

Synthesis of catalyst (1PMF-imp) by impregnation method

Under a well ventilated fume hood, a slurry of magnesium oxide (3.193 g) in 50 mL methanol and 10 mL distilled water was prepared in a 250 mL polypropylene beaker. Under stirring, a sub-stoichiometric amount of hydrofluoric acid (1.2 equivalents, 7 mL 40% aq.) was added dropwise. After dissolution of MgO in aqueous HF, the slow precipitation of MgF_{2-x}(OH)_x took place and the reaction mixture was stirred for an additional 1 h. Afterwards, the resulting slurry was further heated in a water bath at 80 °C until complete evaporation of solvent and formation of a powder of MgF_{2-x}(OH)_x which was dried in an oven at 100 °C. The resulting

support was then dispersed in methanol and a solution of palladium acetate (1 wt %) in methanol (10 mL) was added dropwise to the support slurry. The solution was stirred for 1 h, and then the excess solvent was removed by heating the solution at 80 °C in a water bath until formation of a powder. The prepared catalyst (1PMF-imp) was then dried in an oven at 100 °C for 1 h and subsequently heated at 250 °C in air for 5 h.

Catalyst characterizations

Powder X-ray diffraction (P-XRD) analysis

The prepared catalysts were characterized by X-ray diffraction using PAN analytical X'Pert Pro Dual Goniometer diffractometer. The diffractometer consist of X'celerator solid state detector with $\text{CuK}\alpha$ ($\lambda=1.5406\text{\AA}$, 40kV, 30mA) radiation and a Ni filter. The X-ray diffraction pattern of sample was collected in the range of $2\theta = 20\text{-}80^\circ$ with a step size of 0.02° and scan rate of 4° min^{-1} .

BET surface area measurements

The BET surface area of the catalysts was determined by the N_2 sorption at -196°C , using Autosorb Quanta Chrome equipment. Prior to N_2 adsorption, the sample was evacuated at 200°C under vacuum. The specific surface area was determined according to the BET equation.

Fourier transformed infrared spectroscopic studies (FTIR)

The Fourier Transform Infrared (FT-IR) spectra of the samples were recorded on a Thermo Nicolet Nexus 670 IR instrument using DTGS detector. KBr pellets technique was used to prepare the samples and the spectra were recorded with a resolution of 4 cm^{-1} in the range of $4000\text{-}400 \text{ cm}^{-1}$ averaged over 100 scans.

Electron microscopy

The morphology of samples were determined using scanning electron microscopy (SEM) on a FEI quanta 200 3D dual beam ESEM instrument having thermionic emission tungsten filament in the 3 nm range at 30 kV. The particle size and d-spacing value was determined using Transmission electron microscopy and analysis was done on a Tecnai G2-20 FEI instrument operating at an accelerating voltage of 300 kV. Before analysis, the powder samples were ultrasonically dispersed in isopropanol, and two drops of isopropanol containing the solid were deposited on a carbon coated copper grid.

Catalysis

General procedure for catalytic hydrogenations of imines

Imine reagents (0.055 mmol, around 0.1 g depending the substrate) and catalyst (1PMF-ppt) (0.005 g, 5wt.%, 0.013 mol% of Pd) were introduced in a Schlenk tube. After a vacuum purge, methanol (5 mL) was added under nitrogen and the flask connected to a balloon filled with hydrogen. After 3 vacuum-hydrogen purges, the reaction mixture was heated at the given temperature under stirring for specific time. In order to follow the progress of the reaction,

aliquots (0.1 mL) were taken at defined times, filtered through a pad of Celite, and washed with CH₂Cl₂ (3 mL). The combined solvents were evaporated under reduced pressure and products were analysed by ¹H NMR. At the end of the reaction, solvent was evaporated under vacuum and the crude product was directly purified by flash chromatography or by preparative TLC.

General procedure for catalytic hydrogenations of *N*-heterocycles

A 50 mL stainless-steel autoclave equipped with a magnetic stir bar was charged with the *N*-heterocycle reagent (0.055 mmol, around 0.1 g depending the substrate), catalyst (1PMF-ppt) or (1PMF-imp) (0.005 g, 5wt.%, 0.013 mol% of Pd) and methanol (5 mL). The autoclave was then filled with hydrogen at a pressure of 20 bar after 3 purges. The reaction mixture was heated at 90 °C under stirring for defined time. At the end of the reaction, after cooling and depressurization, the solvent was evaporated under vacuum and the crude product was directly isolated by flash chromatography or preparative TLC.

Procedure for catalyst recycling

The catalyst recycling study was carried out by using catalyst (1PMF-ppt) and imine **1a** under optimized reaction conditions: 0.5 g imine **1a**, 0.05 g catalyst (1PMF-ppt) (10 wt % catalyst with respect to substrate, 0.027 mol% of Pd), 15.0 mL methanol solvent, balloon H₂, 27 °C, 2 h. At the end of the reaction, the catalyst was separated from the reaction mixture by centrifugation and the separated catalyst was washed with methanol for 2-3 times. Afterwards, the resulting solid was dried in an oven at 80 °C and subsequently used as catalyst for the next reaction under identical experimental conditions. The same procedure was repeated for the next three recycle assays.

Pd leaching test

The leaching test was carried out to check any Pd leaching in the reaction mixture under optimized reaction conditions. A mixture of imine **1a** (0.5 g) and catalyst (1PMF-ppt) (0.05 g catalyst, 10 wt.% with respect to substrate, 0.027 mol%) was stirred in methanol (15 mL) by bubbling H₂ at 27 °C for 2 h. The catalyst was then separated from the reaction mixture by centrifugation and the supernatant was further allowed to react under identical reaction conditions without the catalyst.

Procedure for preparation of ICP samples

ICP-AES analysis of prepared catalyst was done by using Spectro Arcos spectrometer. The samples were prepared by dissolving the catalyst into a minimum amount of freshly prepared aqua regia solution (1:3, nitric acid and hydrochloric acid), if necessary the solutions were heated up to 80 °C. After dissolution and cooling of the samples, the prepared solutions were diluted in 100 mL volumetric flasks using ultrapure water (Millipore™), which were subjected to the ICP analysis. Metal leaching of the catalyst was studied by ICP-AES analysis before and after the catalytic reactions.

The BET surface area measurements of fresh and used catalysts (1PMF-ppt) showed close values (105 vs 106 m²/g, respectively) with similar pore size and pore volume (Figure S1, Table S1).




Figure S1. BET surface area analysis of pattern of fresh and used catalyst (1PMF-ppt).


Table S1. Surface characterization of fresh and used catalyst

Catalyst	Surface area (m ² /g)	Pore size (nm)	Pore volume (cc/g)
Fresh- (1PMF-ppt)	106	4.8	0.25
Used- (1PMF-ppt)	105	4.9	0.25

III) Characterization of compounds.

Hydrogenation of aldimines


N-benzylaniline **2a**^{S1}



¹H NMR (300 MHz, CDCl₃): δ = 4.03 (bs, 1H, NH), 4.35 (s, 2H, CH₂), 6.65 (d, ³J = 8.2 Hz, 2H, H_{Ar}), 6.75 (t, ³J = 7.3 Hz, 1H, H_{Ar}), 7.17 (t, ³J = 7.4 Hz, 2H, H_{Ar}), 7.35 (m, 5H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ = 48.4 (CH₂), 112.9 (2CH), 117.7 (1CH), 127.3 (1CH), 127.6 (2CH), 128.7 (2CH), 129.3 (2CH), 139.5 (C), 148.3 (C, CN).


N-benzyl-4-methylaniline **2b**^{S9}



¹H NMR (300 MHz, CDCl₃): δ = 2.16 (s, 3H, CH₃), 4.23 (s, 2H, CH₂), 6.50 (d, ³J = 8.4 Hz, 2H, CH), 6.90 (d, ³J = 8.0 Hz, 2H, CH), 7.29 (m, 5H, CH).

¹³C NMR (75 MHz, CDCl₃): δ = 20.5 (CH₃), 48.9 (CH₂), 113.3 (CH), 127.1 (C), 127.3 (CH), 127.7 (CH), 128.7 (CH), 129.9 (CH), 139.6 (C), 145.7 (C).


N-(4-Fluorophenyl)benzenemethanamine **2c**^{S10}



¹H NMR (300 MHz, CDCl₃): δ = 3.83 (br s, 1H, NH), 4.31 (s, 2H, CH₂), 6.66 (m, 2H, H_{Ar}), 6.89 (m, 2H, H_{Ar}), 7.33 (m, 5H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ = 49.1 (CH₂), 113.8 (d, 2CH_{meta}, J_{C-F} = 7.5 Hz), 115.8 (d, 2CH_{ortho}, J_{C-F} = 22.5 Hz), 127.5 (CH), 127.6 (2CH), 128.8 (2CH), 139.3 (C, CN), 144.5 (d, C_{para}, J_{C-F} = 2.3 Hz), 156.0 (d, C_{ipso}, J_{C-F} = 234.0 Hz).


N-(2-methoxybenzyl)aniline **2d**^{S11}



¹H NMR (300 MHz, CDCl₃): δ = 3.88 (s, 3H, OCH₃), 4.36 (s, 2H, CH₂), 6.71 (m, 3H, H_{Ar}), 6.93 (m, 2H, H_{Ar}), 7.19 (m, 1H, H_{Ar}), 7.27 (m, 1H, H_{Ar}), 7.33 (dd, ³J = 7.3 Hz, 1H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ = 43.7 (CH₂), 55.4 (OCH₃), 110.4 (CH), 113.4 (2CH), 117.6 (CH), 120.7 (CH), 127.4 (C), 128.5 (CH), 129.1 (CH), 129.3 (2CH), 148.4 (C), 157.6 (C).


***N*-(furan-2-ylmethyl)aniline 2e^{S12}**



¹H NMR (300 MHz, CDCl₃): δ = 3.83 (bs, 1H), 4.34 (d, ³*J* = 0.8 Hz, 2H, CH₂), 6.26 (qd, ³*J* = 3.2 Hz, 1H, H_{fur}), 6.34 (dd, ³*J* = 3.3 Hz, 1H, H_{fur}), 6.70 (m, 2H, H_{Ar}), 6.78 (m, 1H, H_{Ar}), 7.21 (m, 2H, H_{Ar}), 7.39 (dd, ³*J* = 1.9 Hz, 1H, H_{fur}).

¹³C NMR (75 MHz, CDCl₃): δ = 41.5 (CH₂), 107.1 (CH), 110.5 (CH), 113.3 (2CH), 118.2 (CH), 129.4 (2CH), 142.1 (CH), 147.6 (C), 152.8 (C).


***N*-(cyclohexylmethyl)-4-methylaniline 2f^{S13}**



¹H NMR (300 MHz, CDCl₃): δ = 0.98 (m, 2H, CH₂), 1.25 (m, 3H, CH₃), 1.59 (m, 1H), 1.77 (m, 5H, 3CH₂), 2.25 (s, 3H, CH₃), 2.95 (d, ³*J* = 6.6 Hz, 2H, CH₂), 3.60 (bs, 1H, NH), 6.55 (d, ³*J* = 8.4 Hz, 2H, CH), 6.99 (d, ³*J* = 8.4 Hz, 2H, CH).

¹³C NMR (75 MHz, CDCl₃): δ = 20.5 (CH₃), 26.1 (CH₂), 26.8 (CH₂), 31.4 (CH₂), 37.7 (CH), 51.2 (CH₂), 113.1 (CH), 126.3 (C), 129.8 (CH), 146.4 (C).

***N*-Benzyl-butyl-amine 2g^{S14}**




¹H NMR (300 MHz, CDCl₃): δ = 0.94 (t, ³*J* = 7.3 Hz, 3H, CH₃), 1.36 (m, 2H, CH₂), 1.53 (m, 2H, CH₂), 2.66 (t, ³*J* = 7.2 Hz, 2H, CH₂), 3.82 (s, 2H, N-CH₂), 7.31 (m, 5H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ = 14.1 (CH₃), 20.6 (CH₂), 32.2 (CH₂), 49.3 (CH₂), 54.1 (CH₂), 127.0 (CH), 128.3 (2CH), 128.5 (2CH), 140.5 (C).

Hydrogenation of ketimines


N-(1-phenylethyl)aniline **4a**^{S1}



¹H NMR (300 MHz, CDCl₃): δ = 1.51 (d, ³*J* = 6.3 Hz, 3H, CH₃), 4.10 (1s, 1H, NH), 4.49 (q, ³*J* = 6.69 Hz, 1H, CH), 6.51 (d, ³*J* = 8.64 Hz, 2H, H_{Ar}), 6.64 (t, ³*J* = 7.2 Hz, 1H, H_{Ar}), 7.09 (m, 2H, H_{Ar}), 7.24 (m, 1H, H_{Ar}), 7.34 (m, 4H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ = 25.1 (CH₃), 53.7 (CH), 113.5 (2CH), 117.4 (CH), 125.9 (2CH), 127.0 (CH), 128.8 (2CH), 129.2 (2CH), 145.3 (C), 147.4 (C, CN).


4-fluoro-*N*-(1-phenylethyl)aniline **4b**^{S5}



¹H NMR (300 MHz, CDCl₃): δ = 1.50 (d, ³*J* = 6.7 Hz, 3H, CH₃), 4.41 (q, ³*J* = 6.7 Hz, 1H, CH), 6.44 (m, 2H, H_{Ar}), 6.78 (m, 2H, H_{Ar}), 7.31 (m, 5H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ = 25.2 (CH₃), 54.3 (CH), 114.3 (d, 2CH_{meta}, *J*_{C-F} = 7.3 Hz), 115.5 (d, 2CH_{ortho}, *J*_{C-F} = 22.2 Hz), 125.9 (2CH), 127.1 (CH), 128.8 (2CH), 143.6 (d, C_{para}, *J*_{C-F} = 1.1 Hz), 145.1 (C, CN), 156.0 (d, C_{ipso}, *J*_{C-F} = 233.4 Hz).


4-methyl-*N*-(1-phenylethyl)aniline **4c**^{S15}



¹H NMR (300 MHz, CDCl₃): δ = 1.53 (d, ³*J* = 6.7 Hz, 3H, CH₃), 2.22 (s, 3H, CH₃), 4.48 (q, ³*J* = 6.7 Hz, 1H, CH), 6.46 (d, ³*J* = 7.9 Hz, 1H, CH), 6.93 (d, ³*J* = 8.0 Hz, 1H, CH), 7.24 (m, 1H), 7.37 (m, 4H, CH).


¹³C NMR (75 MHz, CDCl₃): δ = 20.5 (CH₃), 25.2 (CH₃), 53.8 (CH), 113.5 (CH), 125.9 (CH), 126.5 (C), 126.9 (CH), 128.7 (CH), 129.7 (CH), 145.1 (C), 145.5 (C).

2-ethyl-*N*-(1-phenylethyl)aniline **4d**^{S16}



¹H NMR (300 MHz, CDCl₃): δ = 1.37 (s, 3H, CH₃ Et), 1.61 (d, *J* = 6.59 Hz, 3H, CH₃), 2.63 (q, ³*J* = 7.54 Hz, 2H, CH₂), 4.0 (bs, 1H, NH), 4.58 (q, ³*J* = 6.59 Hz, 1H), 6.44 (dd, ³*J* = 1.00 Hz, 1H, H_{Ar}), 6.70 (td, ³*J* = 7.39 Hz, 1H, H_{Ar}), 7.0 (m, 1H, H_{Ar}), 7.12 (m, 1H, H_{Ar}), 7.27 (m, 1H, H_{Ar}), 7.38 (m, 4H, H_{Ar}). ¹³C NMR (75 MHz, CDCl₃): δ = 13.0 (CH₃), 24.1 (CH₂), 25.4 (CH₃), 53.4 (CH), 111.5 (CH), 117.1 (CH), 125.9 (2CH), 126.9 (2CH), 127.3 (C), 127.8 (CH), 128.7 (2CH), 144.5 (C), 145.4 (C). HRMS (EI): calculated for C₁₆H₂₀N (M⁺), 226.3407; found, 226.15903.


***N*-(1-phenylpropyl)aniline 4e^{S1}**



¹H NMR (300 MHz, CDCl₃): δ= 0.96 (t, ³J= 7.4 Hz, 3H, CH₃), 1.83 (m, 2H, CH₂), 4.06 (bs, 1H, NH), 4.23 (t, ³J= 6.7 Hz, 1H, CH), 6.52 (d, ³J= 7.7 Hz, 2H, H_{Ar}), 6.63 (t, ³J= 7.3 Hz, 1H, H_{Ar}), 7.08 (t, ³J= 7.9 Hz, 2H, H_{Ar}), 7.21 (m, 1H, H_{Ar}), 7.31 (m, 4H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ= 10.9 (CH₃), 31.8 (CH₂), 59.9 (CH), 113.4 (2CH), 117.3 (CH), 126.6 (2CH), 127.1 (CH), 128.6 (2CH), 129.2 (2CH), 144.0 (C), 147.6 (C, CN).


***N*-benzhydrylaniline 4f^{S1}**



¹H NMR (300 MHz, CDCl₃): δ= 5.50 (s, 1H, CH), 6.57 (d, ³J= 7.7 Hz, 2H, H_{Ar}), 6.71 (t, ³J= 7.3 Hz, 1H, H_{Ar}), 7.12 (t, ³J= 7.5 Hz, 2H, H_{Ar}), 7.29 (m, 10H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ= 63.2 (CH), 113.7 (2CH), 117.9 (CH), 127.5 (2CH), 127.7 (4CH), 128.9 (4CH), 129.3 (2CH), 143.1 (2C), 147.6 (C, CN).


***N*-Benzylbutan-1-amine 4g^{S17}**



¹H NMR (300 MHz, CDCl₃): δ= 0.87 (t, ³J= 1.0 Hz, 3H, CH₃ *n*-Bu), 1.29 (m, 2H, CH₂), 1.37 (d, ³J= 6.6 Hz, 3H, CH₃), 1.46 (m, 2H, CH₂), 2.45 (m, 2H, CH₂), 3.76 (q, ³J= 6.6 Hz, 1H, CH), 7.23 (m, 2H, H_{Ar}), 7.33 (m, 3H, H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ= 14.1 (CH₃), 20.6 (CH₂), 24.4 (CH₃), 32.4(CH₂), 47.5(CH₂), 58.6 (CH), 126.7 (2CH), 127.0 (CH), 128.5 (2CH), 145.4(C).


***N*-cyclohexylaniline 4h^{S18}**



¹H NMR (300 MHz, CDCl₃): δ= 1.25 (m, 6H), 1.75 (m, 2H), 2.06 (m, 2H), 3.25 (non, ³J= 3.7 Hz, 1H), 6.59 (d, ³J= 7.6 Hz, 2H_{Ar}), 6.67 (t, ³J= 7.3 Hz, 1H_{Ar}), 7.16 (t, ³J= 7.9 Hz, 2H_{Ar}).

¹³C NMR (75 MHz, CDCl₃): δ= 25.2 (2CH₂), 26.1 (CH₂), 33.5 (2CH₂), 51.9 (CH), 113.4 (2CH), 117.1 (CH), 129.5 (2CH), 147.4 (C).

Cyclohexanamine 4i CAS [108-91-8]^{S19}




¹H NMR (300 MHz, CDCl₃): δ= 1.03 (m, 2H), 1.21 (m, 3H), 1.62 (m, 1H), 1.72 (m, 2H), 1.85 (m, 2H), 2.54 (m, 1H).

¹³C NMR (75 MHz, CDCl₃): δ= 25.5 (2CH₂), 26.4 (CH₂), 34.5 (2CH₂), 53.2 (CH).

Hydrogenation of heterocycles


1,2,3,4-tetrahydroquinoline 6a^{S20}



¹H NMR (300 MHz, CDCl₃): δ = 1.95 (m, 2H, CH₂), 2.77 (t, ³J = 6.4 Hz, 2H, CH₂), 3.25 (t, ³J = 5.5 Hz, 2H, CH₂), 6.48 (d, ³J = 7.8 Hz, 1H, CH), 6.61 (t, ³J = 7.3 Hz, 1H, CH), 6.88 (m, 2H, CH).

¹³C NMR (75 MHz, CDCl₃): δ = 22.3 (CH₂), 27.1 (CH₂), 42.1 (CH₂), 114.4 (CH), 117.1 (CH), 121.6 (C), 126.9 (CH), 129.6 (CH), 144.8 (C).


2-methyl-1,2,3,4-tetrahydroquinoline 6b^{S21}



¹H NMR (300 MHz, CDCl₃): δ = 1.27 (d, ³J = 6.3 Hz, 3H, CH₃), 1.65 (m, 1H), 1.94 (m, 1H), 2.79 (m, 2H), 3.43 (m, 1H), 6.62 (d, ³J = 7.9 Hz, 1H), 6.69 (t, ³J = 7.4 Hz, 1H), 7.05 (m, 2H).

¹³C NMR (75 MHz, CDCl₃): δ = 22.6 (CH₃), 26.6 (CH₂), 30.2 (CH₂), 47.2 (CH), 114.1 (CH), 117.0 (CH), 121.1 (C), 126.7 (CH), 129.3 (CH), 144.8 (C).


1,2,3,4-tetrahydroquinolin-8-ol 6c^{S22}



¹H NMR (300 MHz, acetone-d₆): δ = 1.88 (m, 2H), 2.71 (m, 2H), 3.31 (m, 2H), 6.33 (t, ³J = 7.6 Hz, 1H), 6.43 (d, ³J = 7.6 Hz, 1H), 6.53 (d, ³J = 7.7 Hz, 1H).

¹³C NMR (75 MHz, acetone-d₆): δ = 23.1 (CH₂), 27.6 (CH₂), 42.2 (CH₂), 112.4 (CH), 116.2 (CH), 121.4 (CH), 121.9 (C), 134.9 (C), 144.2 (C).


1,2,3,4-tetrahydroquinolin-5-ol 6d^{S23}



¹H NMR (300 MHz, acetone-d₆): δ = 1.84 (m, 2H), 2.61 (t, ³J = 6.5 Hz, 2H), 3.19 (t, ³J = 5.4 Hz, 2H), 6.01 (d, ³J = 8.0 Hz, 1H), 6.07 (d, ³J = 6.1 Hz, 1H), 6.65 (t, ³J = 7.9 Hz, 1H), 7.85 (bs, 1H, OH).

¹³C NMR (75 MHz, acetone-d₆): δ = 21.5 (CH₂), 22.8 (CH₂), 42.0 (CH₂), 103.8 (CH), 106.9 (CH), 108.6 (C), 127.2 (CH), 147.4 (C), 156.2 (C).

Methyl 1,2,3,4-tetrahydroquinoline-2-carboxylate 6g^{S24}



¹H NMR (300 MHz, CDCl₃) δ = 2.04 (m, 1H), 2.30 (m, 1H), 2.79 (m, 2H), 3.79 (s, 3H, CH₃), 3.90 (dd, ³J = 3.8 Hz, 1H), 4.10 (bs, 1H, NH), 6.61 (d, ³J = 8.0 Hz, 1H), 6.67 (t, ³J = 7.6 Hz, 1H), 7.01 (m, 2H).

¹³C NMR (75 MHz, CDCl₃) δ = 24.7, 25.8, 52.4, 53.9, 114.6, 117.7, 120.6, 127.1, 129.1, 142.9, 173.8.


Piperidine CAS [110-89-4] 8a^{S25}



¹H NMR (300 MHz, CDCl₃): δ= 1.41 (bs, 6H), 2.67 (bs, 4H).

¹³C NMR (75 MHz, CDCl₃): δ= 25.0 (CH₂), 27.1 (2CH₂), 47.3 (2CH₂).


Piperazine CAS [110-85-0] 8b^{S25}



¹H NMR (300 MHz, CDCl₃): δ= 1.42 (bs, 1H, 2NH), 2.65 (bs, 8H).

¹³C NMR (75 MHz, CDCl₃): δ= 47.1 (CH₂).


4a,9,9a,10-tetrahydroacridine 8c^{S26}



¹H NMR (300 MHz, CDCl₃): δ= 4.06 (s, 2H, CH₂), 5.96 (bs, 1H, NH), 6.67 (d, ³J= 3.1 Hz, 2H), 6.87 (t, ³J= 2.9 Hz, 2H), 7.09 (m, 4H).

¹³C NMR (75 MHz, CDCl₃): δ= 31.5 (CH₂), 113.5 (CH), 120.1 (C), 120.8 (CH), 127.1 (CH), 128.7 (CH), 140.2 (C).


1,2,3,4-tetrahydrobenzo[f]quinoline 8d^{S27}



¹H NMR (300 MHz, CDCl₃): δ= 2.16 (m, 2H), 3.09 (t, ³J= 6.5 Hz, 2H), 3.39 (t, ³J= 5.5 Hz, 2H), 3.94 (bs, 1H, NH), 6.82 (d, ³J= 8.7 Hz, 1H), 7.28 (t, ³J= 7.0 Hz, 1H), 7.49 (t, ³J= 7.0 Hz, 1H), 7.57 (d, ³J= 8.7 Hz, 1H), 7.74 (d, ³J= 8.0 Hz, 1H), 7.80 (d, ³J= 8.5 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃): δ= 22.4 (CH₂), 22.8 (CH₂), 41.8 (CH₂), 111.9 (C), 118.4 (CH), 121.3 (CH), 121.7 (CH), 126.4 (CH), 127.5 (CH), 127.9 (C), 128.5 (CH), 133.6 (C), 142.0 (C).


Indoline CAS [496-15-1] 8e^{S28}



¹H NMR (300 MHz, CDCl₃): δ= 3.06 (t, ³J= 8.2 Hz, 2H), 3.59 (t, ³J= 8.3 Hz, 2H), 6.75 (m, 2H), 7.05 (t, ³J= 7.5 Hz, 1H), 7.14 (d, ³J= 7.3 Hz, 1H).

¹³C NMR (75 MHz, CDCl₃): δ= 29.9 (CH₂), 47.4 (CH₂), 109.7 (CH), 118.9 (CH), 124.8 (CH), 127.3 (CH), 129.5 (C), 151.4 (C).

2-Methyl-indoline CAS [6872-06-6] 8f^{S29}



¹H NMR (300 MHz, CDCl₃): δ= 1.30 (d, 2H), 2.66 (dd, ³J= 7.7 Hz, 1H), 3.15 (dd, ³J= 8.5 Hz, 1H), 3.65 (bs, 1H), 4.02 (m, 1H), 6.62 (d, ³J= 7.7 Hz, 1H), 6.71 (t, ³J= 7.4 Hz, 1H), 7.03 (t, ³J= 7.6 Hz, 1H), 7.08 (d, ³J= 7.2 Hz, 1H).


^{13}C NMR (75 MHz, CDCl_3): δ = 22.3 (CH_3), 37.8 (CH_2), 55.3 (CH), 109.4 (CH), 118.7 (CH), 124.8 (CH), 127.3 (CH), 129.1 (C), 150.9 (C).

IV) References


- S1) J. S. M. Samec and J. E. Backvall *Chem. Eur. J.*, 2002, **8**, 2955-2961.
- S2) H. Luo, K. Chen, H. Jiang and S. Zhu, *Org. Lett.*, 2016, **18**, 5208-5211.
- S3) D. Blanco-Ania, P. H. H. Hermkens, L. A. J. M. Sliedregt, H. W. Scheeren and F. P. J. T. Rutjes, *Tetrahedron*, 2009, **65**, 5393-5401.
- S4) S. E. Denmark, N. Nakajima, C. M. Stiff, O. J.-C. Nicaise, M. Kranz, *Adv. Synth. Catal.*, 2008, **350**, 1023-1045.
- S5) Y. Yamamoto, T. Koizumi, K. Katagiri, Y. Furuya, H. Danjo, T. Imamoto and K. Yamaguchi, *Org. Lett.*, 2006, **8**, 6103-6106.
- S6) D. Pei, Z. Wang, S. Wei, Y. Zhang, J. Sun, *Org. Lett.*, 2006, **8**, 5913-5915.
- S7) J. Barluenga, A. Jimenez-Aquino, F. Aznar, C. Valdes, *J. Am. Chem. Soc.* 2009, **131**, 4031-4041.
- S8) a) V. R. Acham, A. V. Biradar, M. K. Dongare, E. Kemnitz and S. B. Umbarkar, *ChemCatChem*, 2014, **6**, 3182-3191; b) R. S. Kokane, V. R. Acham, A. B. Kulal, E. Kemnitz, M. K. Dongare and S. B. Umbarkar, *ChemistrySelect*, 2017, **2**, 10618-10627.
- S9) D. B. Bagal, R. A. Watile, M. V. Khedkar, K. P. Dhake and B. M. Bhanage, *Catal. Sci. Technol.*, 2012, **2**, 354-358.
- S10) A. Kumar and A. G. Samuelson, *Eur. J. Org. Chem.*, 2011, **2011**, 951-959.
- S11) M. Zhang, H. Yang, Y. Zhang, C. Zhu, W. Li, Y. Cheng and H. Hu, *Chem. Commun.*, 2011, **47**, 6605-6607.
- S12) C. C. Lee and S. T. Liu, *Chem. Commun.*, 2011, **47**, 6981-6983.
- S13) B. Li, J. Zheng, W. Zeng, Y. Li and L. Chen, *Synthesis*, 2017, **49**, 1349-1355.
- S14) N. Shankaraiah, N. Markandeya, V. Srinivasulu, K. Sreekanth, Ch. S. Reddy, L. S. Santos and A. Kamal, *J. Org. Chem.*, 2011, **76**, 7017-7026.
- S15) A. Heutling, F. Pohlki and S. Doye, *Chem. Eur. J.*, 2004, **10**, 3059-3071.
- S16) Y. Corre, W. Iali, M. Hamdaoui, X. Trivelli, J.-P. Djukic, F. Agbossou-Niedercorn and C. Michon, *Catal. Sci. Technol.*, 2015, **5**, 1452-1458.
- S17) A. V. Malkov, S. Stončius, K. N. MacDougall, A. Mariani, G. D. McGeoch, P. Kočovský, *Tetrahedron*, 2006, **62**, 264-284.
- S18) D. W. Ma, Q. Cai and H. Zhang, *Org. Lett.*, 2003, **5**, 2453-2455.
- S19) H. J. Schneider, V.; Hoppen, *J. Org. Chem.*, 1978, **43**, 3866-3873.
- S20) T. Kubo, C. Katoh, K. Yamada, K. Okano, H. Tokuyama and T. Fukuyama, *Tetrahedron*, 2008, **64**, 11230-11236.
- S21) V. Sridharan, C. Avendano and J. C. Menendez, *Tetrahedron*, 2007, **63**, 673-681.
- S22) F. Fache, *Synlett*, 2004, **2004**, 2827-2829.
- S23) P. A. Vadola and D. Sames, *J. Org. Chem.*, 2012, **77**, 7804-7814.
- S24) A. M. Maj, I. Suisse, C. Hardouin and F. Agbossou-Niedercorn, *Tetrahedron*, 2013, **69**, 9322-9328.
- S25) G. Ellis and R. G. Jones, *J. Chem. Soc., Perkin Transactions 2*, 1972, **1972**, 437-440.
- S26) P. Nandi, J. L. Dye and J. E. Jackson, *J. Org. Chem.*, 2009, **74**, 5790-5792.
- S27) R. H. Fish, J. L. Tan and A. D. Thormodsen, *Organometallics*, 1985, **4**, 1743-1747.
- S28) F. Xu, B. Simmons, R. A. Reamer, E. Corley, J. Murry and D. Tschäen, *J. Org. Chem.*, 2008, **73**, 312-315.
- S29) A. Kulkarni, W. Zhou and B. Torok, *Org. Lett.*, 2011, **13**, 5124-5127.

V) ^1H , ^{13}C NMR spectra of isolated compounds.

Compound 2a ^1H NMR CDCl_3



Compound 2a ^{13}C NMR CDCl_3





Compound 2b ¹H NMR CDCl₃


7.281
7.276
7.251
7.245
7.225
7.203
7.180
7.164
6.919
6.893
6.513
6.506
6.491
6.485

4.228

2.159
2.086



Compound 2b ¹³C NMR CDCl₃





Compound 2c ¹H NMR CDCl₃

7.339
7.328
7.319
7.317
7.313
7.306
7.299
6.930
6.923
6.908
6.901
6.894
6.880
6.872
6.606
6.598
6.591
6.583
6.576
6.569
6.561

4.305



3.826




Compound 2c ¹³C NMR CDCl₃

157.64
154.52
144.56
144.53
139.33
128.80
127.64
127.45
115.95
115.65
113.92
113.82

49.12





Compound 2d¹H NMR CDCl₃



Compound 2d ^{13}C NMR CDCl_3



157.55
148.37
129.29
129.08
128.45
127.37
120.66
117.63
113.35
110.40

55.43
43.71



Compound 2e ¹H NMR CDCl₃

7.213
7.188
7.184
7.167
7.163
7.160
6.767
6.745
6.742
6.739
6.718
6.690
6.686
6.667
6.664
6.661
6.657
6.324
6.318
6.313
6.307
6.236
6.233
6.230
6.225
6.222
4.309
3.834



Compound 2e ^{13}C NMR CDCl_3

— 152.80

— 147.67

— 142.05

— 129.35



— 118.19

— 113.31


— 110.46

— 107.14


— 41.57




Compound 2f ¹H NMR CDCl₃



Compound 2f ¹³C NMR CDCl₃



Compound 2g ¹H NMR CDCl₃



Compound 2g ^{13}C NMR CDCl_3

— 140.52
— 128.49
— 128.26
— 127.00



— 54.16

— 49.25


— 32.29

— 20.60


— 14.11



Compound 4a $^1\text{H NMR CDCl}_3$



Compound 4a ^{13}C NMR CDCl_3





Compound 4b ¹H NMR CDCl₃


7.329
7.306
7.239
6.808
6.779
6.750
6.447
6.432

4.417
4.394

1.510
1.486



Compound 4b ¹³C NMR CDCl₃





Compound 4c ¹H NMR CDCl₃

7.407
7.384
7.366
7.343
7.318
7.281
7.278
7.271
7.267
7.246
6.944
6.918
6.478
6.451


4.519
4.496
4.474
4.452

2.216


1.544
1.523
1.521



Compound 4c ¹³C NMR CDCl₃



Compound 4d ¹H NMR CDCl₃





Compound 4d ^{13}C NMR CDCl_3

145.38
144.53
128.74
127.82
127.33
126.94
125.89
117.14
111.47


53.44

25.37
24.10


13.00



Compound 4e ¹H NMR CDCl₃




Compound 4e ^{13}C NMR CDCl_3




Compound 4f ¹H NMR CDCl₃


7.344
7.322
7.297
7.282
7.276
7.269
7.260
7.253
7.150
7.125
7.121
7.097
6.738
6.713
6.688
6.591
6.564
5.502




Compound 4f ^{13}C NMR CDCl_3



Compound 4g ¹H NMR CDCl₃





Compound 4g ^{13}C NMR CDCl_3




Compound 4h ¹H NMR CDCl₃



7.258
7.185
7.179
7.161
7.157
7.139
7.132
6.693
6.690
6.687
6.666
6.641
6.617
6.614
6.589
6.586
3.266
3.253
3.241
3.220
2.089
2.079
2.063
2.059
2.047
2.036
1.798
1.785
1.772
1.754
1.741
1.732
1.634
1.437
1.403
1.393
1.382
1.359
1.352
1.343
1.310
1.276
1.266
1.258
1.248
1.237
1.212
1.199
1.170
1.164
1.137
1.129





Compound 4h ^{13}C NMR CDCl_3



Compound 4i ¹H NMR CDCl₃





Compound 4i ¹³C NMR CDCl₃




Compound 6a ¹H NMR CDCl₃

7.260
6.986
6.960
6.936
6.634
6.631
6.609
6.585
6.582
6.493
6.467


3.324
3.306
3.288
2.791
2.769
2.748
1.988
1.967
1.959
1.951
1.947
1.938
1.930
1.908




Compound 6a ^{13}C NMR CDCl_3



Compound 6b ¹H NMR CDCl₃





Compound 6b ^{13}C NMR CDCl_3



Compound 6c ^1H NMR CDCl_3

6.545
6.520
6.444
6.418
6.351
6.326
6.315

3.326
3.308
3.290
2.721
2.712
2.700
2.679
2.088
2.079
2.071
2.064
2.057
1.900
1.879
1.864



Compound 6c ^{13}C NMR CDCl_3

206.42

144.17

134.86

121.96

121.43

120.89

118.80

116.16

112.35

105.57

42.16

41.40

30.67

30.41

30.15

29.90

29.64

29.38



29.13

27.56

24.02

23.69



23.13




Compound 6d ¹H NMR CDCl₃

6.667
6.640
6.086
6.060
6.029
6.002

3.211
3.193
3.174
2.630
2.609
2.587
2.084
2.074
2.065
2.058
2.050
2.043
2.036
1.864
1.846
1.843
1.828





Compound 6d ^{13}C NMR CDCl_3




Compound 6₉ ¹H NMR CDCl₃

7.047
7.022
6.994_s
6.966
6.694
6.671
6.645
6.624
6.597

4.084
4.071
4.055
4.042
3.792
2.853
2.834
2.823
2.807
2.790
2.771
2.329
2.317
2.292
2.286
2.274
2.069
2.058
2.040
2.027
2.014



Compound 6g ¹³C NMR CDCl₃





Compound 8a ^1H NMR CDCl_3


7.260

2.668


1.409




Compound 8a ^{13}C NMR CDCl_3



Compound 8b ^1H NMR CDCl_3




Compound 8b ^{13}C NMR CDCl_3



77.58
77.16
76.73



47.12




Compound 8c ¹H NMR CDCl₃

7.260
7.119
7.094
7.089
7.063
6.886
6.882
6.861
6.857
6.836
6.833
6.687
6.660
5.964

— 4.062





Compound 8c ^{13}C NMR CDCl_3



Compound 8d ¹H NMR CDCl₃

7.498
7.494
7.489
7.470
7.466
7.314
7.311
7.288
7.284
7.281
7.265
7.262
6.834
6.805

3.942
3.410
3.403
3.392
3.373
3.115
3.093
3.072
2.203
2.181
2.174
2.166
2.163
2.152
2.145
2.123





Compound 8d ¹³C NMR CDCl₃

142.03
133.58
128.50
127.88
127.48
127.20
126.35
121.72
121.29
118.44
117.99
113.98
111.87

77.58
77.16
76.74

41.78



22.82
22.36




Compound 8e ¹H NMR CDCl₃

7.259
7.151
7.127
7.070
7.045
7.020
6.787
6.762
6.749
6.724

3.618
3.591
3.563
3.086
3.058
3.030



Compound 8e ^{13}C NMR CDCl_3





Compound 8f ¹H NMR CDCl₃

7.258
7.103
7.079
7.053
7.027
7.002
6.735
6.729
6.711
6.686
6.637
6.611

4.044
4.036
4.023
4.016
3.995
3.990
3.969
3.656
3.197
3.169
3.146
3.117
2.689
2.663
2.638
2.612

1.318
1.297



Compound 8f ^{13}C NMR CDCl_3

